Medivation, Inc. Announces Participation at Upcoming Investor Conference

SAN FRANCISCO, CA--(Marketwire - December 26, 2011) - Medivation, Inc. (NASDAQ: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following investor conference:

• The JP Morgan 30th Annual Healthcare Conference on January 10 at 3:00pm Pacific Time at the Westin St. Francis in San Francisco.

Dr. Hung will provide an overview of Medivation and its clinical development programs.

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Astellas and Pfizer, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer and mild-to-moderate Alzheimer's disease. For more information, please visit us at www.medivation.com.